Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.usj.es/handle/123456789/1020
Título : | Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected HealthcareWorkers |
Autor: | Algarate, Sonia
Serrano, Laura Bueno, Jessica Herrero Cortina, Beatriz Alvarado, Elena Gonzalez-Barriga, Maria T. Ducons, Maria Montero-Marco, Jesica Arnal, Sara Acha, Beatriz Riesgo, Maria Taboada, Ana Sanz-Burillo, Pilar Yuste, Cristina Benito, Rafael |
Palabras clave : | SARS-CoV-2; Booster vaccine; Post-vaccine IgG antibody persistence |
Fecha de publicación: | 27-jun-2023 |
Citación : | Algarate, S.; Serrano, L.; Bueno, J.; Herrero-Cortina, B.; Alvarado, E.; González-Barriga, M.T.; Ducons, M.; Montero-Marco, J.; Arnal, S.; Acha, B.; et al. Persistence of Anti-S1 IgG against SARS-CoV-2 Eight Months after the Booster Dose of Vaccine in Naive and Previously Infected HealthcareWorkers. Int. J. Mol. Sci. 2023, 24, 10713. https:// doi.org/10.3390/ijms241310713 |
Resumen : | Our aim was to evaluate the immune response of healthcare workers included in the RIPOVAC study, after receiving a booster dose (third dose), in terms of intensity and persistence of induced antibodies. In the second phase of the RIPOVAC study, between December 2021 and January 2022, eight months after the second dose, 389 voluntary, immunocompetent, non-pregnant healthcare workers received a booster dose of SARS-CoV-2 vaccine, and a serum sample was obtained. Two groups of patients were established: with and without previous SARS-CoV-2 infection. In order to quantify anti-S1 IgG (AU/mL) we used CMIA (Abbott). All of the health workers were anti-S IgG positive 8 months after receiving the booster dose of the vaccine, with a mean of 17,040 AU/mL. In 53 patients without previous infection, antibody levels increased by a mean of 10,762 AU/mL. This figure is seven times higher than the one produced after the second dose (1506 AU/mL). The booster dose produces a robust elevation of the antibody level, which persists at 8 months, with levels significantly higher than those reached after the second dose, which allow one to predict a persistence of more than one year. The study demonstrates the efficacy of the booster dose of anti-SARS-CoV-2 vaccines. |
URI : | https://repositorio.usj.es/handle/123456789/1020 |
ISSN : | 1661-6596 |
Aparece en las colecciones: | Artículos de revistas |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Persistence of Anti-S1 IgG against SARS-CoV-2.pdf | 927,39 kB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons